Self-Reported Gastrointestinal Symptoms in Type 2 Diabetes Improve With an Intensive Lifestyle Intervention: Results From the Action for Health in Diabetes (Look AHEAD) Clinical Trial.
In Brief This article reports on an investigation of whether an intensive lifestyle intervention (ILI) would reduce gastrointestinal symptoms over 4 years of follow-up for participants in the Action for Health in Diabetes (Look AHEAD) trial compared to a diabetes support and education (DSE) group. Look AHEAD is a randomized, multicenter trial comparing overweight and obese adults with type 2 diabetes treated with ILI versus DSE. ILI, and weight loss in general, had beneficial effects on gastrointestinal (GI) symptoms, with some variability in the strength of the effect depending on the specific symptom and time course. Potential modifiers were analyzed, yet ILI retained an association with improvement in GI symptoms.
Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC.
Rebecca H
RH
Neiberg
Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC.
Jared J
JJ
Rejeski
Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC.
William B
WB
Applegate
Departments of Medicine and Epidemiology, Johns Hopkins Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, MD.
Jeanne M
JM
Clark
Diabetes Epidemiology and Clinical Research Section, National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ.
William C
WC
Knowler
Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA.
George A
GA
Bray
Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC.
Mark A
MA
Espeland
Departments of Medicine and Epidemiology, Johns Hopkins Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, MD ; Department of Health, Behavior & Society, Johns Hopkins Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, MD.
Lawrence J
LJ
Cheskin